TNV262 / Tenvie Therapeutics - LARVOL DELTA

Dosing begins in trial testing treatment for MS, obesity (Multiple Sclerosis News Today) - "The Phase 1a/1b study will test single and multiple doses of TNV262 in healthy volunteers and people with obesity. The main goal of the early study is to evaluate the safety, tolerability, and pharmacological properties of the experimental medication....The company plans to report preliminary trial data later this year. Pending positive results, Tenvie expects to initiate Phase 2 studies in MS, as well as cardiovascular disease and obesity."

New P2 trial • P1 data • Trial status • Multiple Sclerosis • Obesity